Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
10
|
| pubmed:dateCreated |
1998-10-28
|
| pubmed:abstractText |
In order to develop new strategies for the treatment of relapsed or refractory acute myeloid leukemia, the German AML Cooperative Group performed a prospective multicenter phase II study to evaluate the antileukemic efficacy of aclarubicin 60 mg/m2/day and etoposide 100 mg/m2/day each given for 5 days. Of 37 heavily pretreated evaluable patients (median age 42 years, range 18-81) 15 (40%) achieved a remission after one or two courses of treatment consisting of nine complete (24%) and six partial remissions (16%). Fourteen (38%) cases were non-responders and eight (22%) patients suffered from early deaths. Disease-free survival for patients in remission and overall survival were 3.2 months each. The median duration of critical neutropenia <500/microl was 27 days. The most frequent non-hematologic side-effects were stomatitis (WHO III/IV, 48%), infections (40%), nausea/vomiting (26%) and diarrhea (24%). Cardiac toxicity was mild. This study suggests a substantial antileukemic efficacy and an acceptable toxicity of aclarubicin in combination with etoposide in heavily pretreated patients with advanced acute myeloid leukemia, and warrants further evaluations in a more favorable stage of the disease.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
0887-6924
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
12
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1522-6
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9766494-Aclarubicin,
pubmed-meshheading:9766494-Adolescent,
pubmed-meshheading:9766494-Adult,
pubmed-meshheading:9766494-Aged,
pubmed-meshheading:9766494-Aged, 80 and over,
pubmed-meshheading:9766494-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9766494-Disease-Free Survival,
pubmed-meshheading:9766494-Etoposide,
pubmed-meshheading:9766494-Female,
pubmed-meshheading:9766494-Humans,
pubmed-meshheading:9766494-Leukemia, Myeloid, Acute,
pubmed-meshheading:9766494-Leukocyte Count,
pubmed-meshheading:9766494-Male,
pubmed-meshheading:9766494-Middle Aged,
pubmed-meshheading:9766494-Neutropenia,
pubmed-meshheading:9766494-Prospective Studies,
pubmed-meshheading:9766494-Recurrence,
pubmed-meshheading:9766494-Stomatitis,
pubmed-meshheading:9766494-Survival Rate
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial. German AML Cooperative Group.
|
| pubmed:affiliation |
Department of Hematology and Oncology, Georg-August-University, Göttingen, Germany.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|